PureTech Health plc PRTC.L · Stock Open PureTech Health plc in new tab
PureTech Health plc Analysis (PRTC.L)
Is PureTech Health plc a good investment? PureTech Health plc (PRTC.L) is currently trading at 120.20 GBX. Market analysts have a consensus price target of 389.36 GBX. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 9.92. This relatively low multiple may signal that PureTech Health plc is undervalued compared to historical market norms.
Earnings Schedule: PureTech Health plc is expected to release its next earnings report on Aug. 27, 2026. The market consensus estimate for Forward EPS is -0.30.
Investor FAQ
Does PureTech Health plc pay a dividend?
No, it does not currently pay a dividend.
What asset class is PureTech Health plc?
PureTech Health plc is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Aug. 27, 2026. The company currently has a trailing EPS of -0.35.
Company Profile
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody. The company also develops SPT-300, a Glyphed oral prodrug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development and oral therapies based on defined bacterial consortia that is in phase 3 clinical stage. PureTech Health plc was incorporated in 2015 and is based in Boston, Massachusetts.
Community Discussion